Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.
2.

p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment.

Feng Z.

Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001057. doi: 10.1101/cshperspect.a001057. Review.

3.

The coordinate regulation of the p53 and mTOR pathways in cells.

Feng Z, Zhang H, Levine AJ, Jin S.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9. Epub 2005 May 31.

4.

The LKB1 tumor suppressor negatively regulates mTOR signaling.

Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC.

Cancer Cell. 2004 Jul;6(1):91-9.

5.

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.

Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR.

Biochem J. 2008 Jun 1;412(2):211-21. doi: 10.1042/BJ20080557.

PMID:
18387000
6.

PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.

Akundi RS, Zhi L, B├╝eler H.

Neurobiol Dis. 2012 Jan;45(1):469-78. doi: 10.1016/j.nbd.2011.08.034. Epub 2011 Sep 16.

7.
8.

AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression.

Li J, Jiang P, Robinson M, Lawrence TS, Sun Y.

Carcinogenesis. 2003 May;24(5):827-34.

PMID:
12771025
9.

Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.

Miyazaki M, McCarthy JJ, Esser KA.

FEBS J. 2010 May;277(9):2180-91. doi: 10.1111/j.1742-4658.2010.07635.x.

10.

Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase.

Das F, Ghosh-Choudhury N, Dey N, Mandal CC, Mahimainathan L, Kasinath BS, Abboud HE, Choudhury GG.

J Biol Chem. 2012 Feb 3;287(6):3808-22. doi: 10.1074/jbc.M111.246397. Epub 2011 Dec 19.

11.

AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.

Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB.

Oncogene. 2012 Apr 12;31(15):1949-62. doi: 10.1038/onc.2011.394. Epub 2011 Sep 12.

12.

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

Budanov AV, Karin M.

Cell. 2008 Aug 8;134(3):451-60. doi: 10.1016/j.cell.2008.06.028. Erratum in: Cell. 2009 Jan 23;136(2):378.

13.

Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.

Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N.

J Biol Chem. 2005 Sep 16;280(37):32081-9. Epub 2005 Jul 15.

14.

PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes PTEN & LKB1 in human uterine leiomyomas.

Makker A, Goel MM, Mahdi AA, Bhatia V, Das V, Agarwal A, Pandey A.

Indian J Med Res. 2016 May;143(Supplement):S112-S119. doi: 10.4103/0971-5916.191808.

16.

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ.

J Clin Invest. 2007 Mar;117(3):730-8. Epub 2007 Feb 8.

17.
18.

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ.

J Clin Invest. 2003 Oct;112(8):1223-33.

19.

Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle.

Ching JK, Luebbert SH, Collins RL 4th, Zhang Z, Marupudi N, Banerjee S, Hurd RD, Ralston L, Fisher JS.

Exp Physiol. 2013 Feb;98(2):526-35. doi: 10.1113/expphysiol.2012.066357. Epub 2012 Aug 31.

20.

The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.

Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO.

Cancer Res. 2006 Dec 1;66(23):11331-40.

Supplemental Content

Support Center